참고문헌
- Abbas S, Lugthart S, Kavelaars FG, et al (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood, 116, 2122-6. https://doi.org/10.1182/blood-2009-11-250878
- Ahmad F, Mandava S, Das BR (2010). Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest, 28, 63-73. https://doi.org/10.3109/07357900903095649
- Ahmad F, D'Souza W,Mandava S, et al (2011). Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute myeloid leukemia: determination of incidence, distribution patterns, and report of a novel KIT mutation. Leuk Lymphoma, 52, 865-76. https://doi.org/10.3109/10428194.2011.552137
- Ahmad F, Mandava S, Das BR (2009). Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol, 27, 90-7. https://doi.org/10.1002/hon.883
- Ahmad F, Rajput S, Mandava S, et al (2012). Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients. Genet Test Mol Biomarkers, 16, 707-15. https://doi.org/10.1089/gtmb.2011.0317
- Boissel N, Nibourel O, Renneville A, et al (2010). Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol, 28, 3717-23. https://doi.org/10.1200/JCO.2010.28.2285
- Brenner C, Fuks F (2006). DNA methyltransferases:facts, clues, mysteries. Curr Top Microbiol Immunol, 301, 45-66.
- Chen T, Li E (2006). Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol, 301, 179-201.
- Chotirat S, Thongnoppakhun W, Promsuwicha O, et al (2012). Molecular alterations of Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol, 5, 1-10. https://doi.org/10.1186/1756-8722-5-1
- Chou WC, Hou HA, Chen CY, et al (2010). Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 115, 2749-54. https://doi.org/10.1182/blood-2009-11-253070
- Delhommeau F, Dupont S, Della Valle V, et al., 2009) Mutation in TET2 in myeloid cancers. N Engl J Med, 360, 2289-301. https://doi.org/10.1056/NEJMoa0810069
- Fernandez-Mercado M, Yip BH, Pellagatti A, et al (2012). Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics. PLOS ONE, 7, 42334. https://doi.org/10.1371/journal.pone.0042334
- Fried I, Bodner C, Pichler MM, et al (2012). A. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia, Haematologica, 97, 246-50. https://doi.org/10.3324/haematol.2011.051581
- Gaidzik V, Dohner K (2008). Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol, 35, 346-55. https://doi.org/10.1053/j.seminoncol.2008.04.005
- Green CL, Evans CM, Zhao L, et al (2011). The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 118, 409-12. https://doi.org/10.1182/blood-2010-12-322479
- Grimwade D, Walker H, Oliver F, et al (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial, The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-33.
- Gross S, Cairns RA, Minden MD, et al (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med, 207, 339-44. https://doi.org/10.1084/jem.20092506
- Ho PA, Alonzo TA, Kopecky KJ, et al (2010). Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia, 24, 909-13. https://doi.org/10.1038/leu.2010.56
- Ho PA, Kutny MA, Alonzo TA, et al (2011). Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer, 57, 204-9. https://doi.org/10.1002/pbc.23179
- Holz-Schietinger C, Matje DM, Reich NO (2012). Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem, 287, 30941-51. https://doi.org/10.1074/jbc.M112.366625
- Hou HA, Kuo YY, Liu CY, et al (2012). DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 119, 559-68. https://doi.org/10.1182/blood-2011-07-369934
- Jeha S, Smith FO, Estey E, et al (2002). Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk Res, 26, 399-402. https://doi.org/10.1016/S0145-2126(01)00149-7
- LaRochelle O, Bertoli S, Vergez F, et al (2011). Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience, Oncotarget, 2, 850-61.
- Lee SH, Jo SH, Lee SM, et al (2004). Role of NADP- dependent isocitrate dehydrogenase(NADP_-ICDH) on cellular defence against oxidative injury bygammarays. Int J Radiat Biol, 80, 635-42. https://doi.org/10.1080/09553000400007680
- Ley TJ, Ding L,Walter MJ, et al (2010). DNMT3A mutations in Acute myeloid leukemia. N Engl J Med, 36, 2424-33.
- Lin J, Qian J, Yao DM, et al (2011). Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Clin Biochem, 44, 779-83. https://doi.org/10.1016/j.clinbiochem.2011.04.014
- Lin J, Yao D-m, Qian J, et al (2011). Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. PLOS ONE, 6, 1-7.
- Marcucci G, Metzeler KH, Schwind S, et al (2012). Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol, 30, 742-50. https://doi.org/10.1200/JCO.2011.39.2092
- Marcuccii G, Maharry K, Wu YZ, et al (2010). IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol, 28, 2348-55. https://doi.org/10.1200/JCO.2009.27.3730
- Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 36, 1058-66.
- Markova J, Michkova P, Burckova K, et al (2012). Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol, 88, 128-35. https://doi.org/10.1111/j.1600-0609.2011.01716.x
- Mrozek K, Dohner H, Bloomfield CD (2007). Influence of new molecular Prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol, 14, 106-14. https://doi.org/10.1097/MOH.0b013e32801684c7
- Paschka P, Schlenk RF, Gaidzik VI, et al (2010). IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 28, 3636-43. https://doi.org/10.1200/JCO.2010.28.3762
- Patel JP, Gonen M, Figueroa ME, et al (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 366, 1079-89. https://doi.org/10.1056/NEJMoa1112304
- Patel KP, Ravandi F, Ma D, et al (2011). Acute Myeloid Leukemia With IDH1 or IDH2 Mutation: Frequency and Clinicopathologic Features. Am J Clin Pathol, 135, 35-45. https://doi.org/10.1309/AJCPD7NR2RMNQDVF
- Qiao C, Sun C, Zhang SJ, et al (2011). Analysis of DNMT3a gene mutations in acute myelogenous leukemia, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19, 303-7.
- Rakheja D, Konoplev S, Medeiros LJ, et al (2012). IDH mutations in acute myeloid leukemia, Hum Pathol, 43, 1541-51. https://doi.org/10.1016/j.humpath.2012.05.003
- Renneville A, Boissel N, Nibourel O, et al (2012). Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 26, 1247-54. https://doi.org/10.1038/leu.2011.382
- Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al (2012). Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood, 119, 5824-31. https://doi.org/10.1182/blood-2011-07-367961
- Schnittger S, Haferlach C, Ulke M, et al (2010). IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-96. https://doi.org/10.1182/blood-2010-02-267955
- Slovak ML, KopeckyKJ, Cassileth PA, et al (2000). Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood, 96, 4075-83.
- Swerdlow SH, Campo E, Harris NL, et al (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. Lyon, International Agency for Research on Cancer (IARC).
- Takahashi S (2011). Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol, 4, 13. https://doi.org/10.1186/1756-8722-4-13
- Takahashi SJ (2011). Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol, 36, 1-11.
- Thol F, Damm F, Ludeking A, et al (2011). Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol, 29, 2889-96. https://doi.org/10.1200/JCO.2011.35.4894
- Thol F, Damm F, Wagner K, et al (2010). Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 116, 614-6. https://doi.org/10.1182/blood-2010-03-272146
- Wagner K, Damm F, Gohring G, et al (2010). Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol, 28, 2356-64. https://doi.org/10.1200/JCO.2009.27.6899
- Zhang Y, Wei H, Wang M, et al (2011). Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res, 35, 1301-6. https://doi.org/10.1016/j.leukres.2011.01.019
- Zou Y, Zeng Y, Zhang DF, et al (2010). IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun, 402, 378-83. https://doi.org/10.1016/j.bbrc.2010.10.038
피인용 문헌
- Survival Outcome of AML Patients with and without TKD Mutations vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10995
- Overall Survival in Acute Myeloid Leukaemia Patients with and without Internal Tandem Duplication vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.393
- Prognostic Value of a CYP2B6 Gene Polymorphism in Patients with Acute Myeloid Leukemia vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4583
- Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4095
- Demographic and Clinical Characteristics of Adult Acute Myeloid Leukemia - Tertiary Care Experience vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.357
- Acute Myeloid Leukemia: Clinical Spectrum of 125 Patients vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.369
- Outcome of Inversion 16 in TKD Positive and Negative Acute Myeloid Leukemia Patients vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2343
- Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone vol.143, pp.5, 2017, https://doi.org/10.1007/s00432-016-2331-0
- Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies vol.10, pp.2, 2018, https://doi.org/10.3390/cancers10020049
- Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes vol.144, pp.6, 2018, https://doi.org/10.1007/s00432-018-2627-3